You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 4
  • 518 Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers

Article info

Article menu

Download PDFPDF

Ovarian cancer
518 Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers
Free

Authors

Citation

Banerjee S, Oaknin A, Sanchez-Simon I, et al
518 Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers
International Journal of Gynecologic Cancer 2020;30:A86-A87.

Publication history

  • First published December 4, 2020.
Online issue publication 
February 04, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.